Vanda Pharmaceuticals (VNDA) Rating Reiterated by Oppenheimer
Vanda Pharmaceuticals (NASDAQ:VNDA)‘s stock had its “buy” rating reissued by research analysts at Oppenheimer in a research note issued on Monday.
VNDA has been the subject of a number of other reports. Zacks Investment Research cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Piper Jaffray Companies increased their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, September 14th. Finally, ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $21.50.
Vanda Pharmaceuticals (NASDAQ VNDA) traded down $0.05 during mid-day trading on Monday, reaching $14.20. The company had a trading volume of 625,700 shares, compared to its average volume of 618,500. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99. The firm has a market cap of $630.11, a PE ratio of -44.38 and a beta of 1.29.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. During the same period last year, the firm posted ($0.01) EPS. The business’s revenue was up 7.3% on a year-over-year basis. equities analysts expect that Vanda Pharmaceuticals will post -0.44 earnings per share for the current year.
In other news, CFO James Patrick Kelly sold 9,155 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.35, for a total value of $140,529.25. Following the transaction, the chief financial officer now directly owns 144,721 shares in the company, valued at approximately $2,221,467.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total value of $2,933,928.00. Following the completion of the transaction, the insider now owns 1,031,848 shares in the company, valued at $15,787,274.40. The disclosure for this sale can be found here. Insiders sold a total of 209,483 shares of company stock worth $3,205,205 over the last quarter. Corporate insiders own 7.60% of the company’s stock.
Large investors have recently bought and sold shares of the company. Legal & General Group Plc boosted its position in shares of Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter worth $196,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Vanda Pharmaceuticals in the 3rd quarter worth $277,000. Voya Investment Management LLC boosted its position in shares of Vanda Pharmaceuticals by 29.7% in the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its position in shares of Vanda Pharmaceuticals by 46.3% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 6,487 shares during the last quarter. Institutional investors and hedge funds own 88.43% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.